Stopeck, Alison T <br/><br/>
A phase 2 trial of standard-dose cyclophosphamide, doxorubicin, vincristine, prednisone (CHOP) and rituximab plus bevacizumab for patients with newly diagnosed diffuse large B-cell non-Hodgkin lymphoma: SWOG 0515.  [electronic resource] 

 -  Blood  Aug 2012 
 - 1210-7 p.  digital 
<br/><br/> Publication Type: Clinical Trial, Phase II; Journal Article; Multicenter Study; Research Support, N.I.H., Extramural 
<br/><br/><label>ISSN: </label>1528-0020 
<br/><br/><label>Standard No.: </label>10.1182/blood-2012-04-423079  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Adult<br/>Aged<br/>Aged, 80 and over<br/>Antibodies, Monoclonal, Humanized--administration & dosage<br/>Antibodies, Monoclonal, Murine-Derived--administration & dosage<br/>Antineoplastic Combined Chemotherapy Protocols--administration & dosage<br/>Bevacizumab<br/>Cyclophosphamide--administration & dosage<br/>Dose-Response Relationship, Drug<br/>Doxorubicin--administration & dosage<br/>Female<br/>Humans<br/>Lymphoma, Large B-Cell, Diffuse--diagnosis<br/>Male<br/>Middle Aged<br/>Neoadjuvant Therapy<br/>Prednisone--administration & dosage<br/>Rituximab<br/>Standard of Care<br/>Survival Analysis<br/>Treatment Outcome<br/>Vincristine--administration & dosage<br/>Young Adult